Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids

British Journal of Clinical Pharmacology

Volumn 61, Issue 3, 2006, Pages 326-335

  Morrish, Glynn A ^a   Foster, David J R ^a   Somogyi, Andrew A ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Glucuronidation; Inhibition; Methadone; Morphine; Noncompetitive; Stereoselectivity

Indexed keywords

2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; DEXTROPROPOXYPHENE; DINORLEVACETYLMETHADOL; LEVACETYLMETHADOL; METHADONE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; NORACYMETHADOL; OPIATE; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; ENANTIOMER; ENZYME KINETICS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MALE; PRIORITY JOURNAL; STEREOCHEMISTRY; STRUCTURAL HOMOLOGY;

ALAMETHICIN; ANALGESICS, OPIOID; HUMANS; IONOPHORES; METHADONE; METHADYL ACETATE; MICROSOMES, LIVER; MORPHINE DERIVATIVES; PROPOXYPHENE;

EID: 33644922665     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02573.x     Document Type: Article

References (54)

1. Pasternak GW Bodnar RJ Clark JA Inturrisi CE. Morphine-6-glucuronide, a potent mu agonist Life Sci 1987 41 2845 9
2. Klepstad P Kaasa S Borchgrevink PC. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine Eur J Clin Pharmacol 2000 55 713 9
3. Portenoy RK Thaler HT Inturrisi CE Friedlander-Klar H Foley KM. The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function Clin Pharmacol Ther 1992 51 422 31
4. Smith GD Smith MT. Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat Pain 1995 62 51 60
5. Gong QL Hedner J Bjorkman R Hedner T. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat Pain 1992 48 249 55
6. Gardmark M Karlsson MO Jonsson F Hammarlund-Udenaes M. Morphine-3-glucuronide has a minor effect on morphine antinociception. Pharmacodynamic modeling J Pharm Sci 1998 87 813 20
7. Sjögren P Thunedborg LP Christrup L Hansen SH Franks J. Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories Acta Anaesthesiol Scand 1998 42 1070 5
8. Penson RT Joel SP Bakhshi K Clark SJ Langford RM Slevin ML. Randomized placebo-controlled trial of the activity of the morphine glucuronides Clin Pharmacol Ther 2000 68 667 76
9. Penson RT Joel SP Clark S Gloyne A Slevin ML. Limited phase I study of morphine-3-glucuronide J Pharm Sci 2001 90 1810 6
10. Pacifici GM Sawe J Kager L Rane A. Morphine glucuronidation in human fetal and adult liver Eur J Clin Pharmacol 1982 22 553 8
11. Sawe J Kager L Svensson Eng JO Rane A. Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation Br J Clin Pharmacol 1985 19 495 501
12. Wahlstrom A Pacifici GM Lindstrom B Hammar L Rane A. Human liver morphine UDP-glucuronyl transferase enantioselectivity and inhibition by opioid congeners and oxazepam Br J Pharmacol 1988 94 864 70
13. Coughtrie MW Ask B Rane A Burchell B Hume R. The enantioselective glucuronidation of morphine in rats and humans. Evidence for the involvement of more than one UDP-glucuronosyltransferase isoenzyme Biochem Pharmacol 1989 38 3273 80
14. Fisher MB Campanale K Ackermann BL VandenBranden M Wrighton SA. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin Drug Metab Dispos 2000 28 560 6
15. Cheng Z Rios GR King CD Coffman BL Green MD Mojarrabi B Mackenzie PI Tephly TR. Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7 Toxicol Sci 1998 45 52 7
16. Green MD King CD Mojarrabi B Mackenzie PI Tephly TR. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP- glucuronosyltransferase 1A3 Drug Metab Dispos 1998 26 507 12
17. Stone AN Mackenzie PI Galetin A Houston JB Miners JO. Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP- glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7 Drug Metab Dispos 2003 31 1086 9
18. Coffman BL Rios GR King CD Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation Drug Metab Dispos 1997 25 1 4
19. Miners JO Lillywhite KJ Birkett DJ. In vitro evidence for the involvement of at least two forms of human liver UDP-glucuronosyltransferase in morphine 3-glucuronidation Biochem Pharmacol 1988 37 2839 45
20. Dole VP Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction JAMA 1965 193 80 4
21. Mercadante S Casuccio A Fulfaro F Groff L Boffi R Villari P Gebbia V Ripamonti C. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study J Clin Oncol 2001 19 2898 904
22. Codd EE Shank RP Schupsky JJ Raffa RB. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception J Pharmacol Exp Ther 1995 274 1263 70
23. Kristensen K Christensen CB Christrup LL. The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine Life Sci 1995 56 PL45 50
24. Doverty M Somogyi AA White JM Bochner F Beare CH Menelaou A Ling W. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine Pain 2001 93 155 63
25. Iribarne C Berthou F Baird S Dreano Y Picart D Bail JP Beaune P Menez JF. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes Chem Res Toxicol 1996 9 365 73
26. Moody DE Alburges ME Parker RJ Collins JM Strong JM. The involvement of cytochrome P450 3A4 in the N-demethylation of 1-alpha-acetylmethadol (LAAM), norLAAM, and methadone Drug Metab Dispos 1997 25 1347 53
27. Foster DJ Somogyi AA Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4 Br J Clin Pharmacol 1999 47 403 12
28. Trapnell CB Klecker RW Jamis-Dow C Collins JM. Glucuronidation of 3′-azido-3′-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid Antimicrob Agents Chemother 1998 42 1592 6
29. Schwartz EL Brechbuhl AB Kahl P Miller MA Selwyn PA Friedland GH. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection J Acquir Immune Defic Syndr 1992 5 619 26
30. McCance-Katz EF Rainey PM Jatlow P Friedland G. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262) J Acquir Immune Defic Syndr Hum Retrovirol 1998 18 435 43
31. Milne RW Nation RL Reynolds GD Somogyi AA Van Crugten JT. High-performance liquid chromatographic determination of morphine and its 3- and 6-glucuronide metabolites: improvements to the method and application to stability studies J Chromatogr 1991 565 457 64
32. Nelson AC Huang W Moody DE. Variables in human liver microsome preparation: impact on the kinetics of 1-alpha-acetylmethadol (LAAM) n-demethylation and dextromethorphan O-demethylation Drug Metab Dispos 2001 29 319 25
33. Lowry O Rosebrough N Farr A Randall R. Protein measurement with folin phenol reagent J Biol Chem 1951 193 265 75
34. Omura T Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for Its hemoprotein nature J Biol Chem 1964 239 2370 8
35. Mikus G Somogyi AA Bochner F Eichelbaum M. Codeine O-demethylation: rat strain differences and the effects of inhibitors Biochem Pharmacol 1991 41 757 62
36. Rios GR Tephly TR. Inhibition and active sites of UDP- glucuronosyltransferases 2B7 and 1A1 Drug Metab Dispos 2002 30 1364 7
37. Osborne R Joel S Grebenik K Trew D Slevin M. The pharmacokinetics of morphine and morphine glucuronides in kidney failure Clin Pharmacol Ther 1993 54 158 67
38. Wahlstrom A Lenhammar L Ask B Rane A. Tricyclic antidepressants inhibit opioid receptor binding in human brain and hepatic morphine glucuronidation Pharmacol Toxicol 1994 75 23 7
39. Court MH Krishnaswamy S Hao Q Duan SX Patten CJ Von Moltke LL Greenblatt DJ. Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism Drug Metab Dispos 2003 31 1125 33
40. Wu D Otton SV Sproule BA Busto U Inaba T Kalow W Sellers EM. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone Br J Clin Pharmacol 1993 35 30 4
41. Shiran MR Chowdry J Rostami-Hodjegan A Ellis SW Lennard MS Iqbal MZ Lagundoye O Seivewright N Tucker GT. A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment Br J Clin Pharmacol 2003 56 220 4
42. Lawrence AJ Michalkiewicz A Morley JS MacKinnon K Billington D. Differential inhibition of hepatic morphine UDP-glucuronosyltransferases by metal ions Biochem Pharmacol 1992 43 2335 40
43. Doverty M. Acute pain management in methadone maintenance treatment [PhD Thesis]. Adelaide University of Adelaide 2001
44. Mistry M Houston JB. Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine Drug Metab Dispos 1987 15 710 7
45. Boase S Miners JO. In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine Br J Clin Pharmacol 2002 54 493 503
46. Tucker GT Houston JB Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus Br J Clin Pharmacol 2001 52 107 17
47. Foster DJ Somogyi AA White JM Bochner F. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients Br J Clin Pharmacol 2004 57 742 55
48. McLure JA Miners JO Birkett DJ. Nonspecific binding of drugs to human liver microsomes Br J Clin Pharmacol 2000 49 453 61
49. Drummer OH Opeskin K Syrjanen M Cordner SM. Methadone toxicity causing death in ten subjects starting on a methadone maintenance program Am J Forensic Med Pathol 1992 13 346 50
50. Mazoit JX Sandouk P Scherrmann JM Roche A. Extrahepatic metabolism of morphine occurs in humans Clin Pharmacol Ther 1990 48 613 8
51. Wolff T Samuelsson H Hedner T. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration Pain 1995 62 147 54
52. Faura CC Moore RA Horga JF Hand CW McQuay HJ. Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain J Pain Symptom Manage 1996 11 95 102
53. Smith MT Watt JA Cramond T. Morphine-3-glucuronide - a potent antagonist of morphine analgesia Life Sci 1990 47 579 85
54. Bartlett SE Cramond T Smith MT. The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex Life Sci 1994 54 687 94